Phathom Pharmaceuticals, Inc. intends to offer shares of its common stock or pre-funded warrants in an underwritten public offering.
The offering is subject to market and other conditions, with the option for underwriters to purchase additional shares.
Net proceeds will be used for general corporate purposes, including working capital and research expenses.
Offering Details
Phathom Pharmaceuticals plans to offer shares of common stock in a public offering with underwriters managing the process.
Use of Proceeds
The company intends to use the net proceeds for general corporate purposes, including research and development.
Underwriters
Guggenheim Securities and Cantor are acting as joint bookrunning managers for the offering.
- The offering provides Phathom Pharmaceuticals with the opportunity to raise capital for its operations and future projects.
- Investors will closely watch the market conditions and the success of the offering to assess the company's financial strength.
Phathom Pharmaceuticals' decision to opt for a public offering demonstrates its commitment to funding its long-term strategic initiatives and advancing its pipeline of treatments for gastrointestinal diseases.